Stocks Amgen Inc

More

  • genentech_logo.jpg

    I am at the Genentech analyst meeting at the Mandarin Oriental Hotel next to the new Time Warner Center in Columbus Circle in Manhattan. The room is packed with an estimated 300-plus analysts, investors, reporters and Genentech execs.

  • graphic_word_ofthe_street.jpg

    A 200+ point decline turns into a net gain on the Big Board as Standard & Poor's gives the market some confidence that the end is near. Also, oil and gold hit records and more in the Word on the Street.

  • The sign outside Amgen Inc.'s entrance. Thousand Oaks, Calif.

    Scientists advising the Food and Drug Administration said anemia drugs sold by Amgen and Johnson & Johnson should be allowed to stay on the market for chemotherapy patients.

  • Stocks closed higher Thursday after Standard & Poor's delivered the words Wall Street was waiting to hear: The end is in sight.

  • Amgen, the world's biggest biotech company in terms of sales (Genentech dwarfs Amgen in market cap: $86 billion vs. $51 billion) and Dow component Johnson & Johnson avoided a worst-case scenario this afternoon.

  • picks_pans_badge.jpg

    Five-star fund managers are looking past this week's market gyrations and offering investors some promising stock opportunities.

  • Ahead of the big FDA Advisory Committee meeting tomorrow, Amgen held a quick conference call with some reporters this afternoon. The outside panel of experts will be deciding whether to recommend putting more restrictions on the use of the blockbuster drugs used to fight anemia in cancer patients getting chemo. For Johnson and Johnson and especially Amgen, the stakes are high.

  • Following are the day’s biggest winners and losers. Find out why shares of U.S. Steel and Thornburg Mortgage popped while UnitedHealth and Dick's Sporting Goods dropped.

  • Stocks shot up Tuesday after a liquidity announcement from the Federal Reserve.

  • johnson_johnson2_logo.jpg

    Shares of biotech giant Amgen fell as low as $43.14 (a new bottom) this morning after the briefing documents for Thursday's Food and Drug Administration Advisory Committee meeting were posted on the agency's website.

  • Stocks shot up Tuesday after a liquidity announcement from the Federal Reserve.

  • This is a big week for the world's top-two biotechnology companies and their investors. What’s going on and how can you trade it?

  • Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.

  • AMGEN

    This is a big week for the world's top-two biotechnology companies and their investors. Amgen goes before an FDA Advisory Committee Thursday about the side effects of its bread-and-butter franchise Aranesp.

  • web_extra_weekahead_thumb.jpg

    In Friday’s Web Extra find out how the traders recommend playing Wal-Mart, Costco, Pfizer, Amgen and Genentech in the week ahead.

  • bull and bear outside frankfurt stock exchange

    Nasdaq's bear market is likely to persist longer than the pullback in the broader stock market unless the recently battered technology heavyweights make solid comebacks.

  • I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...

  • democrat_drug_money.jpg

    On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...

  • Cramer makes the call on viewers' favorite stocks.

  • picks_pans_badge.jpg

    The time to buy stocks, says Michael Cuggino, is now. The president and portfolio manager of Permanent Portfolio Funds offered CNBC very specific reasons to buy -- and the specific stocks you need.